

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

TYK-nu

RRID:CVCL_1776

Type: Cell Line

Proper Citation

RRID:CVCL_1776

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1776

Proper Citation: RRID:CVCL_1776

Description: Cell line TYK-nu is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:2647872](#), [PMID:3658923](#), [PMID:3782955](#), [PMID:9290701](#), [PMID:11330945](#), [PMID:12417041](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:23839242](#), [PMID:25485619](#), [PMID:25846456](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TYK-nu

Synonyms: TYK-NU, TYKnu, TYKNU

Cross References: CLO:CLO_0037104, EFO:EFO_0006766, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:1039, BioSample:SAMN03471005, BioSample:SAMN10988265, cancercellines:CVCL_1776, Cell_Model_Passport:SIDM00321, CGH-DB:9359-4, ChEMBL-Cells:ChEMBL3308805,

ChEMBL-Targets:CHEMBL1075601, Cosmic:909774, Cosmic:931359, Cosmic:948288, Cosmic:1077283, Cosmic:2582803, Cosmic:2674702, Cosmic-CLP:909774, DepMap:ACH-000430, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909774, GEO:GSM659409, GEO:GSM711725, GEO:GSM851946, GEO:GSM887718, GEO:GSM888811, GEO:GSM1670552, IARC_TP53:27264, JCRB:JCRB0234.0, LiGeA:CCLE_471, LINCX_LDP:LCL-1700, PharmacDB:TYKnu_1614_2019, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_1776, PubChem_Cell_line:CVCL_1776, Wikidata:Q54973461

ID: CVCL_1776

Record Creation Time: 20220427T221638+0000

Record Last Update: 20260905T182613+0000

Ratings and Alerts

No rating or validation information has been found for TYK-nu.

No alerts have been found for TYK-nu.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. NPJ precision oncology, 9(1), 3.

Gudoityte G, et al. (2025) Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. Molecular oncology, 19(9), 2574.

Glossner L, et al. (2025) Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer. Molecular oncology.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T??cells enhances therapeutic specificity. Cell, 188(9), 2372.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Furutake Y, et al. (2024) YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma. *Molecular cancer therapeutics*, 23(11), 1652.

Cumin C, et al. (2022) Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. *Cell reports*, 40(7), 111181.

Javellana M, et al. (2022) Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. *Cancer research*, 82(1), 169.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. *Molecular cancer therapeutics*, 21(4), 647.

Wong-Brown MW, et al. (2022) Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy. *BMC cancer*, 22(1), 100.

Cui C, et al. (2021) Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. *Cell*, 184(12), 3163.

Gonzalez VD, et al. (2021) High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. *Cell reports*, 36(9), 109632.

Curtis M, et al. (2019) Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. *Cell metabolism*, 29(1), 141.